Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years. On February 6, Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia to $4 from $6 and kept an Overweight rating. This adjustment was made as part of a broader review of commercial-stage companies, with the firm updating estimates and price targets following several year-end preliminary reports and ahead of official Q4 2025 results. In Q3, Akebia Therapeutics Inc. (NASDAQ:AKBA) ...

分组1 - Ardelyx reported break-even quarterly earnings per share, matching the Zacks Consensus Estimate of $0.02, with a year-ago comparison of $0.02 per share [1] - The company achieved revenues of $125.22 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 6.51% and showing an increase from $116.13 million year-over-year [2] - Ardelyx shares have increased approximately 15.3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Ardelyx is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $111.28 million, and for the current fiscal year, it is $0.23 on revenues of $534.79 million [7] - The Medical - Drugs industry, to which Ardelyx belongs, is currently ranked in the bottom 47% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Market Overview - The S&P 500 and Dow have risen for nine consecutive months on a total return basis despite rising geopolitical tensions [2] - A potential 5% dip in the market is anticipated in the second half of February due to high optimism and put-to-call ratios, but the bull market remains intact with solid fundamentals [2] Technology Sector Insights - The market is experiencing indiscriminate selling, with a notable increase in short interest in the XLK (Tech ETF) reaching its highest level in years [3] - Software valuations are at their cheapest since 2013, presenting a buying opportunity, as the Carson Group has added to tech and software positions [3] Akebia Therapeutics Inc. (NASDAQ:AKBA) - Akebia reported total revenue of $58.8 million in Q3, with a net income of $540,000, recovering from a $20 million net loss in Q3 2024 [10] - The launch of its dialysis drug Vafseo generated lower-than-expected revenue of $14.3 million, but patient access expanded to 70,000 with over 700 active prescribers [10] - Management anticipates a temporary revenue dip in Q4 due to inventory adjustments but projects growth to resume in Q1 2026, focusing on its 2026 pipeline outlook [11] LiveRamp Holdings Inc. (NYSE:RAMP) - LiveRamp reported a revenue growth of 9% year-over-year to $212 million in FQ3 2026, exceeding expectations [14] - The company has formed a significant strategic partnership with Publicis and expanded its Data Marketplace to include AI models, positioning for double-digit growth in fiscal year 2027 [14] - Subscription net retention has compressed to 101%, and gross margins are expected to dip slightly, with a projected sequential increase in operating expenses of $15 million in FQ4 [15]

Group 1 - Since September 2024, the proportion of southbound capital transactions has rapidly increased to 20%-30%, nearly doubling compared to before 2024 [2][5] - In 2025, both active and passive foreign capital have become synchronous indicators of the Hong Kong stock market, showing no leading characteristics [2][5] - During sharp declines or corrections in the Hong Kong stock market, southbound capital tends to buy against the trend [2][5] Group 2 - Each round of pricing power competition typically begins with the optimization of the Stock Connect policy or the influx of incremental capital, which usually flows into dividend and scarce assets [5] - Net outflows of southbound capital often occur in response to adverse industry policies or external macroeconomic environments, particularly in sectors where foreign capital pricing power is increasing, such as software services, hardware equipment, consumer services, and discretionary retail [5][12] - Industries less likely to experience significant net outflows include those favored by long-term capital, such as banking, telecommunications, and public utilities, unless there are clear adverse policies affecting the sector [5][12] Group 3 - The proportion of medium to long-term capital in the current round of southbound capital inflow into Hong Kong stocks has increased, with insurance capital making 41 stakes, 35 of which are in H-shares, marking the highest record in the past decade [8] - Key industries for increased holdings include discretionary retail, finance (banking, insurance), innovative pharmaceuticals, software services, and hardware equipment [8] Group 4 - Current industries with pricing power for southbound capital and Chinese capital include semiconductors and dividend stocks, while industries lacking pricing power include internet, hardware equipment, software services, home appliances, and media [11][12] - Active management public funds have low pricing power in the Hong Kong stock market, focusing heavily on AI-related CSP giants, electronics, and innovative pharmaceuticals [16]

Core Insights - Akebia Therapeutics Inc. has officially established a rare kidney disease pipeline, focusing on two main product candidates: AKB-097 and praliciguat [1][3] - The company aims to position Vafseo as the standard treatment for anemia in dialysis patients while simultaneously developing a robust pipeline for rare kidney conditions [1] Product Details - Vafseo is an oral treatment for anemia due to chronic kidney disease in adults on dialysis for at least three months, approved in 37 countries, and stimulates endogenous erythropoietin production [2] - AKB-097, previously known as ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to target complement activation at the organ level, potentially reducing infection risks and dosing frequency [3] Financial Transactions - Akebia entered into an Asset Purchase Agreement with Q32 Bio Inc. to acquire global rights to AKB-097, paying an upfront fee of $7 million, with an additional $3 million due six months post-closing [3]

Core Insights - Q32 Bio's shares more than doubled following a strategic deal with Akebia Therapeutics, indicating strong market interest and validation of its complement inhibitor platform [1][3] - The deal involves an upfront payment of $12 million for the Phase complement inhibitor ADX-097, with potential total transaction value reaching $592 million through various milestones [1][3] - The transaction allows Q32 Bio to monetize a key asset while retaining rights to its broader tissue-targeted complement inhibitor platform, which includes ADX-096 for ophthalmologic indications [3] Financial Implications - The divestment of ADX-097 provides immediate cash flow and long-term revenue potential through tiered royalties ranging from low single-digit to mid-teen percentages on future sales [4] - The company plans to refocus on advancing Bempikibart, a treatment for alopecia areata, which represents a strategic pivot that may enhance stock value in 2026 [4] Market Reaction - At its peak, Q32 Bio stock traded nearly 350% above its year-to-date low, but closed the session at $3.82, reflecting a 75% increase on the day [2] - Despite the positive outlook from the Akebia deal, there are concerns regarding the sustainability of the stock's rapid price increase and inherent execution risks associated with biotech investments [5][6]

Core Insights - Q32 Bio Inc. has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, leading to a significant increase in its stock price by 115.07% to $4.71 [1][6] Group 1: ADX-097 Overview - ADX-097 is a humanized anti-C3d Factor H monoclonal antibody fusion protein designed to inhibit complement activation, which is crucial for the innate immune system [2][3] - The drug has potential applications in various conditions related to C3d deposition, including kidney, autoimmune, vascular, and skin diseases [2] Group 2: Financial Terms of the Sale - Q32 Bio will receive $12 million in upfront payments from Akebia, with a structured payment plan including $7 million at signing, $3 million after six months, and $2 million upon achieving a milestone or by the end of 2026 [5] - The total potential payments from Akebia could reach up to $592 million, including development, regulatory, and commercial milestones [5] Group 3: Future Prospects - Q32 Bio retains rights to its tissue-targeted complement inhibitor platform, including other early-stage assets like ADX-096, and is exploring strategic options for these programs [4] - The company expects its cash reserves, combined with the upfront payments and near-term milestones from the ADX-097 sale, to sustain operations into the second half of 2027 [6]

Core Insights - Q32 Bio has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, which allows the company to focus on advancing bempikibart for alopecia areata [1][2][3] - The transaction is expected to provide $12 million in upfront payments and potential total payments of up to $592 million based on future milestones [3][4] - Q32 Bio retains its tissue-targeted complement inhibitor platform, including ADX-096 and other early-stage assets, and is evaluating strategic options for these programs [1][2] Financial Implications - The sale of ADX-097 is projected to extend Q32 Bio's cash runway into the second half of 2027, supporting ongoing clinical trials [2][4] - The upfront payment structure includes $7 million at signing, $3 million at the 6-month anniversary, and $2 million upon achieving a milestone or by the end of 2026 [3] Product Development Focus - Q32 Bio is concentrating on bempikibart (ADX-914), a fully human anti-IL-7R antibody, for the treatment of alopecia areata, with topline data from the SIGNAL-AA Phase 2a trial expected in mid-2026 [2][6] - The company’s tissue-targeted complement platform aims to inhibit complement activation while minimizing systemic effects, differentiating it from current therapies [2][3]

Core Insights - Theravance Biopharma (TBPH) reported third-quarter 2025 adjusted earnings of 4 cents per share, exceeding the Zacks Consensus Estimate of a loss of 3 cents, and improved from an adjusted loss of 6 cents per share in the same quarter last year [1][6] - Total revenues for the third quarter reached $20 million, aligning with the Zacks Consensus Estimate, and reflecting a 19% year-over-year increase driven by collaboration revenues from partner Viatris (VTRS) [1][6] Financial Performance - The revenue for the quarter was solely derived from Viatris' collaboration revenues related to Yupelri (revefenacin) sales [3] - U.S. sales of Yupelri increased by 15% year over year, contributing to the positive financial results [6] - Viatris recorded $71.4 million in U.S. net sales of Yupelri for the third quarter, marking a 15% increase from the previous year [7] Expense Management - Research and development expenses (excluding share-based compensation) totaled $7 million, a decrease of approximately 14.6% from the year-ago quarter [7] - Selling, general and administrative expenses (excluding share-based compensation) rose around 13.8% year over year to $14.8 million [7] Cash Position - As of September 30, 2025, Theravance had cash, cash equivalents, and marketable securities amounting to $332.7 million, down from $338.8 million as of June 30, 2025 [8] Financial Guidance - Theravance reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses (excluding share-based compensation) in the range of $32-$38 million and adjusted SG&A expenses between $50 million and $60 million [9] - The company anticipates share-based compensation expenses of $18-$20 million in 2025 [9] Pipeline Developments - Theravance is developing ampreloxetine, a norepinephrine reuptake inhibitor for treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) [11] - The pivotal phase III CYPRESS study for ampreloxetine has completed enrollment, with top-line data expected in the first quarter of 2026 [11] - An expedited new drug application (NDA) filing for ampreloxetine is planned if the study data are positive, with a request for priority review from the FDA [12]

Core Insights - Mettler-Toledo International (MTD) reported third-quarter 2025 adjusted earnings of $11.15 per share, exceeding the Zacks Consensus Estimate by 4.99%, with a year-over-year increase of 9.2% [1][8] - Net sales reached $1.03 billion, surpassing the Zacks Consensus Estimate by 3.84%, although it represented an 8% decline on a reported basis and a 6% decline on a local currency basis compared to the previous year [1][8] Revenue Breakdown - MTD's revenues are categorized into three segments: Laboratory ($565 million, 54.9% of net sales), Industrial ($406 million, 39.4% of net sales), and Food Retail ($59 million, 5.7% of net sales) [2] - Year-over-year growth in local currency for the segments was 4% for Laboratory, 9% for Industrial, and 5% for Food Retail [2] Geographic Sales Performance - Total sales from the Americas, Europe, and Asia/Rest of the World were $432 million (41.9% of net sales), $293 million (28.4%), and $305 million (29.6%), respectively [3] - Sales in the Americas and Asia/Rest of the World increased by 4% and 1% year-over-year in local currency, while Europe sales remained unchanged [3] Operating Metrics - The gross margin for Q3 2025 was 59.2%, a contraction of 80 basis points year-over-year [4] - Research & Development (R&D) expenses were $51.1 million, up 8.5% year-over-year, while Selling, General & Administrative (SG&A) expenses rose 8.6% to $248.4 million [4] - The adjusted operating margin was 30.1%, declining by 100 basis points year-over-year [5] Financial Position - As of September 30, 2025, Mettler-Toledo's cash and cash-equivalent balance was $69.1 million, an increase from $61.8 million as of June 30 [6] - Long-term debt stood at $2.15 billion, with cash generated from operating activities amounting to $299.4 million and free cash flow at $280.7 million for the quarter [6] Future Guidance - For Q4 2025, Mettler-Toledo anticipates a sales increase of approximately 3% in local currency year-over-year, with adjusted earnings projected between $12.68 and $12.88 per share, reflecting a growth rate of 2% to 4% [7] - For the full year 2025, the company expects local currency sales to increase by about 2% over 2024, with adjusted earnings between $42.05 and $42.25 per share, indicating 2-3% growth [9] - Looking ahead to 2026, Mettler-Toledo forecasts a 4% increase in local currency sales over 2025, with adjusted earnings projected between $45.35 and $46.00 per share, representing an 8-9% growth [9]